...
首页> 外文期刊>Journal of clinical gastroenterology >A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis.
【24h】

A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis.

机译:有症状的原发性硬化性胆管炎的内窥镜治疗二十年经验。

获取原文
获取原文并翻译 | 示例

摘要

GOALS: The current study presents 1 tertiary endoscopy center's 20-year experience using endoscopic therapy to treat patients with symptomatic primary sclerosing cholangitis (PSC). BACKGROUND: Endoscopic therapy for patients with PSC and dominant strictures has been used for more than 20 years, but there is concern that instrumenting a sclerotic biliary tree induces risks that outweigh anticipated benefits. STUDY: In this retrospective chart review, 117 patients with PSC were identified using ICD-9 codes. Patients had a mean age of 47 years (range: 15 to 86 y). Mean duration of follow-up was 8 years (range: 2 to 20 y). Of the 117 identified patients, 106 underwent endoscopic retrograde cholangiopancreatography on one or more occasions (for a total of 317 endoscopic retrograde cholangiopancreatographies), and a subset of 84 patients received endoscopic therapy for treatment of dominant strictures and/or deteriorating clinical status. Actual survival for endoscopically treated patients was compared with predicted survival using the Mayo Clinic natural history model for PSC. RESULTS: Our chart review revealed 23 recognized complications among the 317 procedures performed (7.3%), and no procedure-related deaths. Observed patient survival at years 3 and 4 was significantly higher than that predicted by the Mayo Clinic natural history model for PSC (P=0.021). CONCLUSIONS: Patients with PSC who have a deteriorating clinical course benefited from endoscopic therapy to provide drainage of bile ducts, removal of stones, and/or temporary relief from obstructions, with acceptable procedure-related complications and higher than expected 3-year and 4-year survival.
机译:目标:本研究显示了一家三级内窥镜中心20年来使用内窥镜疗法治疗有症状的原发性硬化性胆管炎(PSC)患者的经验。背景:内窥镜治疗PSC和占位性狭窄的患者已经使用了20多年,但是人们担心,硬化胆管树的植入所带来的风险超过了预期的收益。研究:在此回顾性图表审查中,使用ICD-9代码识别了117例PSC患者。患者的平均年龄为47岁(范围:15至86岁)。平均随访时间为8年(范围:2至20年)。在117例确定的患者中,有106例接受了一次或多次内镜逆行胰胆管造影术(总共317例内镜逆行胰胆管造影术),并且84例患者中的一部分接受了内镜治疗以治疗狭窄狭窄和/或临床状况恶化。使用Mayo Clinic PSC自然历史模型,将经内镜治疗的患者的实际生存与预测的生存进行了比较。结果:我们的图表检查显示,在执行的317例手术中有23例被确认为并发症(7.3%),且无与手术相关的死亡。在第3和第4年观察到的患者存活率显着高于Mayo诊所针对PSC的自然史模型所预测的存活率(P = 0.021)。结论:临床过程恶化的PSC患者受益于内镜治疗,可引流胆管,清除结石和/或暂时解除阻塞,具有与手术相关的可接受的并发症,且比预期的3年和4年高年生存。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号